Article: Trandolapril

Image:Trandolapril.png
Trandolapril
Systematic (IUPAC) name
1-[2-[(1-ethoxycarbonyl-3-phenyl-propyl)amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole- 2-carboxylic acid
Identifiers
CAS number	87679-37-6
ATC code	C09AA10
PubChem	5484727
DrugBank	APRD01269
Chemical data
Formula	C24H34N2O5
Mol. weight	430.537 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	trandolapril 80% (independent of concentration) trandolaprilat 65 to 94% (concentration-dependent)
Metabolism	hepatic
Half life	6hours trandolapril 10hours trandolaprilat
Excretion	?
Therapeutic considerations
Pregnancy cat.	D
Legal status	℞ Prescription only
Routes	oral

Trandolapril is an ACE inhibitor used to treat high blood pressure, it may also be used to treat other conditions. It is marketed by Abbott Laboratories with the brand name Mavik®.

Pharmacology

Trandolapril is a prodrug that is deesterified to trandolaprilat. It is believed to exert its antihypertenive effect through the renin-angiotensin-aldosterone system. Trandolapril has a half life of about 6 hours, and trandolaprilat has a half life of about 10. Trandolaprilat has about 8 times the activity of its parent drug. Approximately 1/3 of Trandolapril and its metabolites are excreted in the urine, and about 2/3 of Trandolapril and its metabolites are excreted in the feces. Serum protein binding of trandolapril is about 80%.

Clinical use

Main article: ACE inhibitor

Its mode of action, indications, side-effects and contraindications are as those of all ACE inhibitors. Two to four (2-4) mg, once daily, is the typical dose range.